[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]

@tom_the_bomb__ Avatar @tom_the_bomb__ ⛏🅾️Ⓜ️💣

⛏🅾️Ⓜ️💣 posts on X about $8750t, $4568t, $6417t, $323m the most. They currently have XXXXX followers and XX posts still getting attention that total XXXXX engagements in the last XX hours.

Engagements: XXXXX #

Engagements Line Chart

Mentions: X #

Mentions Line Chart

Followers: XXXXX #

Followers Line Chart

CreatorRank: XXXXXXXXX #

CreatorRank Line Chart

Social Influence

Social category influence stocks XXXXX% finance XXXXX% exchanges XXXX% social networks XXXX% technology brands XXXX%

Social topic influence $8750t #14, $4568t #3, $6417t #9, $323m 9.09%, $1004m 9.09%, $1034m 9.09%, $236b 9.09%, $425m 9.09%, $1322m 9.09%, $3337m XXXX%

Top accounts mentioned or mentioned by @kirranejam60371 @asininitybeyond @avacta @bigcheese88930 @decscfc1990 @moneycruncher @arianacar58927 @john_lancs @111ben_111

Top assets mentioned Novartis AG (NVS)

Top Social Posts

Top posts by engagements in the last XX hours

"AVA6000 sales ( only scaled market penetration): In X years: STS: $323m SGC: $1004m TNBC: $1034m ---- TOTAL: $2.36B ---- In X years: STS: $425m SGC: $1322m TNBC: $3337m ---- TOTAL: $5.08B ---- #AVCT"
X Link 2025-11-28T09:45Z 3364 followers, 8296 engagements

"Daiichi Sankyo Seagen Pfizer Novartis and Merck are names that have consistently surfaced whenever deal rumours have appeared. When one of them steps forward it changes everything. Look forward to the RNS that finally shows where the smart money has landed. #AVCT"
X Link 2025-12-02T08:54Z 3365 followers, 13K engagements

"Lots of NASDAQ mentions here. IMO its simply Avacta showing BP they have multiple levers they can pull if the price isnt right (yet). If #AVCT follow the standard playbook: X Deliver 1B efficacy. X Announce AA pathway. X Secure strategic partner(s). X Rerate 5-10x. X Then uplist and raise at a much higher valuation shareholders will do very well. Dilution at a 3B valuation is very different to dilution at 300M. Something no shareholder wants to see. I still think we get taken out once they have data on the Beast though. Not long now"
X Link 2025-12-05T18:48Z 3364 followers, 7713 engagements

"@BigCheese88930 @ariana_car58927 All I can do is report them each time. If you're able to as well that would be great. Cheers"
X Link 2025-12-07T21:03Z 3365 followers, XX engagements

"A recent disclosure caught my eye. A leading #oncology KOL listed research funding and personal advisory work for: Daiichi Sankyo ✅ AstraZeneca ✅ Pfizer ✅ Genentech ✅ Seagen ✅ BioNTech ✅ and. #AVCT ✅ She's (1) respected (2) strategically influential and (3) trusted in early phase and ADC decision making. On the MSKCC page it doesnt mention Avacta so Im assuming this is a recent addition potentially linked to the upcoming AVA6103 programme given her breast cancer/TNBC specialism. This type of KOL usually consults for the top tier ADC/oncology players. So it's very good to see @avacta in the"
X Link 2025-11-30T21:38Z 3365 followers, 4085 engagements

"If Biotechs rarely follow a normal path the only constant is good tech leads to partnershipsorbuyouts what happens if you have groundbreaking tech #AVCT #Biotech #Buyout"
X Link 2025-12-10T08:08Z 3365 followers, 1780 engagements